Henry Schein reported Q3 2025 sales of $3.3 billion, up 5.2% year-over-year (4.0% constant currency), with accelerating growth across all segments and solid market share gains. Non-GAAP EPS increased 13.1% to $1.38, driven by a 19-basis point expansion in non-GAAP operating margin to 7.83% and a $28 million remeasurement gain. The company is fully recovered from the 2023 cyber incident and is executing its BOLD+1 strategy, targeting over $200 million in operating income improvements through value creation initiatives with KKR. Management raised 2025 non-GAAP EPS guidance to $4.88-$4.96 and expects 3-4% sales growth, supported by strong share repurchases ($229 million in Q3) and momentum in high-growth technology and implant businesses.
| Metric | Value | Change |
|---|---|---|
| Sales | $3.3 Billion | +5.2% |
| Non-GAAP EPS | $1.38 | +13.1% |
| Non-GAAP Operating Margin | 7.83% | +19 bps |
| Adjusted EBITDA | $295 Million | +10% |
| Operating Cash Flow | $174 Million | +15.2% |
Value Creation & KKR Partnership: Management emphasized a significant expansion of its strategic partnership with KKR, targeting over $200 million in operating income improvements over the next few years through centralization, procurement, and automation. The Board also approved increasing KKR's ownership stake to 19.9%, signaling strong alignment and confidence in the strategic direction. This capital deployment strategy focuses on operational efficiency to support long-term earnings growth.
Post-Cyber Recovery & Market Share Gains: A critical strategic signal is the declaration that the cyber incident is 'fully behind us,' with sales accelerating and market share gains returning, particularly in U.S. dental merchandise and international implants. The company has successfully regained customer trust and is leveraging its restored systems and sales force to drive growth, evidenced by the raised sales guidance for 2025.
Digital & AI Transformation: Henry Schein is aggressively pivoting towards high-growth technology solutions, highlighted by a new partnership with Amazon Web Services (AWS) to integrate generative AI into Dentrix Ascend and Dentally. This move aims to enhance practice management efficiency and patient experience, driving recurring SaaS revenue, which grew with a 20% year-over-year increase in cloud-based customers.
Portfolio Shift to High-Margin Businesses: The BOLD+1 strategy prioritizes shifting the revenue mix towards high-growth, high-margin areas, targeting over 50% of non-GAAP operating income from these segments by 2027, plus 10% from corporate brands. Strong performance in the Global Technology Group (+9.7% sales) and double-digit growth in value implants demonstrate successful execution of this portfolio optimization.
Gross Margin Pressure: Despite operating margin expansion, gross margin declined by 56 basis points year-over-year, driven by product mix shifts in distribution and specialty products, as well as the seasonality of lower-margin flu vaccines. Management noted stabilization in U.S. dental margins, but the mix shift towards lower-margin value implants versus premium implants remains a headwind to profitability in the specialty segment.
Tariff and Inflation Headwinds: Management acknowledged approximately 100 basis points of tariff-related inflation in the U.S., requiring mitigation strategies such as switching manufacturers or absorbing costs. While they believe they can manage this, persistent tariff exposure represents a risk to margin stability if pricing power weakens or supply chain shifts become more costly.
CEO Transition Uncertainty: The announcement of Stanley Bergman's retirement at the end of 2025 introduces a layer of uncertainty regarding the strategic direction and leadership continuity. While the Board search is ongoing and Bergman expressed confidence in the team, the departure of a long-tenured founder-CEO can create volatility until the successor is announced and settles into the role.
Softness in Premium Implants: While value implants showed double-digit growth, premium implants grew only in the low single digits. This mix shift not only pressures margins but also suggests potential competitive pressures or a cautious customer base reluctant to invest in high-end capital equipment, despite the overall recovery narrative.
Overall: Management exhibited a high degree of confidence and optimism, celebrating the company's 30-year anniversary while emphasizing that the cyber incident is 'fully behind us.' Stanley Bergman was reflective yet forward-looking, expressing strong belief in the management team and the BOLD+1 strategy, while Ronald South provided detailed, data-driven financial updates that reinforced the positive outlook.
Confidence: HIGH
$4.88 - $4.96 (Raised)
3% - 4%
Mid-single digits vs 2024
Hedging & Uncertainty: Management generally used confident language ('fully behind us,' 'huge confidence'), but employed hedging when discussing specific future impacts of the value creation plan and the 2026 outlook. Phrases like 'we believe we have the opportunity,' 'expect to start,' and 'should we split that over the next 3 years' indicate uncertainty regarding the exact timing and magnitude of the $200 million efficiency gains. They also hedged on the remeasurement gains, noting they are 'not expecting anything significant in the near future' but leaving the door open.
The cyber incident is fully behind us. - Stanley Bergman, CEO
We believe we have the opportunity to deliver over $200 million of improvements to operating income over the next few years. - Stanley Bergman, CEO
We are raising our 2025 financial guidance... reflecting stable markets and good third quarter financial results. - Ronald South, CFO
I have huge confidence in the management team... and I'm quite in fact, very optimistic about where this will go. - Stanley Bergman, CEO
We're confident we've been taking some share over a period of time. - Ronald South, CFO
Analyst Sentiment: Analysts were largely congratulatory and positive, asking detailed questions about the sustainability of growth, the mechanics of the new value creation program, and margin composition. There was a focus on understanding the 'new normal' post-cyber incident and post-restructuring.
Management Responses: Management was responsive and detailed, particularly Ron South on the financial mechanics and Stanley Bergman on the strategic narrative. They deflected specific questions about 2026 guidance timing but provided clear qualitative color on business momentum and market share.
Analysts focused on the phasing of the $200M cost savings, seeking clarity on how much would drop to the bottom line in 2026 versus future years. Management confirmed it is a multiyear plan but did not quantify the 2026 specific benefit yet.
Questions regarding gross margin sustainability were prominent, specifically the mix impact of value versus premium implants and the stabilization of PPE/glove pricing.
Inquiries into the competitive landscape and market share gains versus general market recovery, with management asserting that gains are driven by execution and service restoration rather than just market growth.
Discussion around the KKR relationship and the implications of the increased ownership stake, with management emphasizing the operational support provided by KKR's Capstone group.
Henry Schein is demonstrating a robust operational recovery following its cyber incident, with accelerating sales growth and expanding operating margins indicating a return to form. The strategic pivot towards higher-margin technology and specialty products, combined with a substantial $200 million value creation program backed by KKR, provides a clear path to high single-digit to low double-digit earnings growth. The aggressive share buyback program and raised guidance underscore management's confidence in the cash generation capabilities and intrinsic value of the business. While CEO transition and margin mix present risks, the valuation appears supported by the strong fundamental turnaround and long-term strategic positioning.
Patient traffic remained steady throughout the quarter, indicating resilient demand for dental and medical procedures despite broader economic fluctuations.
Management noted approximately 100 basis points of tariff-related inflation in the U.S., though they are mitigating this through manufacturer negotiations and supply chain adjustments.
Pricing dynamics have stabilized, with management noting that customers are no longer significantly shifting to lower-priced national brands and glove pricing has stabilized.